Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK119 and AK112 in Advanced Solid Tumors
NCT05689853Phase 2Recruiting
- Sponsor
- Akeso, Inc.
- Start
- Apr 2023
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ambuzutinib in solid tumor, sponsored by Akeso, Inc.. Started Apr 2023; status: recruiting.
02
Drugs
ambuzutinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05689853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05689853.